FDA Submission Update for Prolia (Denosumab) by Amgen
Amgen has submitted a supplemental application for Prolia (denosumab) under BLA125320 with standard review priority.
Asset / Drug
Drug and asset intelligence for Prolia with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.